STOCK TITAN

Guardant Health (GH) co-CEO family trust sells 50,000 shares

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Guardant Health, Inc. Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026. The shares were sold at a weighted average price of $100.32 per share in multiple trades.

After this transaction, 2,096,504 shares of Guardant Health Common Stock are reported as indirectly owned, held by the Talasaz and Eskandari 2017 Family Trust.

Positive

  • None.

Negative

  • None.
Insider Talasaz AmirAli
Role Co-Chief Executive Officer
Sold 50,000 shs ($5.02M)
Type Security Shares Price Value
Sale Common Stock 50,000 $100.32 $5.02M
Holdings After Transaction: Common Stock — 2,096,504 shares (Indirect, Shares held by Talasaz and Eskandari 2017 Family Trust)
Footnotes (1)
  1. [object Object]
Shares sold 50,000 shares Open-market sale on May 12, 2026
Average sale price $100.32 per share Weighted average sales price for 50,000 shares
Price range $100.30–$100.34 per share Range of individual trade prices in the sale
Shares owned after transaction 2,096,504 shares Indirect holdings via Talasaz and Eskandari 2017 Family Trust after sale
open-market sale financial
"The transaction is described as an open-market sale of Common Stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sales price financial
"Represents the weighted average sales price per share."
indirect ownership financial
"Ownership type is reported as indirect, held by a family trust."
Family Trust financial
"Shares held by Talasaz and Eskandari 2017 Family Trust."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Talasaz AmirAli

(Last)(First)(Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Co-Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/12/2026S50,000D$100.32(1)2,096,504IShares held by Talasaz and Eskandari 2017 Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.30 to $100.34. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Remarks:
/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz05/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Guardant Health (GH) disclose for AmirAli Talasaz?

Guardant Health disclosed that Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026. The transaction was executed through the Talasaz and Eskandari 2017 Family Trust.

At what price were the Guardant Health (GH) shares sold in the latest Form 4?

The 50,000 Guardant Health shares were sold at a weighted average price of $100.32 per share. Footnotes state the sales occurred in multiple transactions, at prices ranging from $100.30 to $100.34 across the executed trades.

How many Guardant Health (GH) shares does AmirAli Talasaz report owning after the sale?

Following the reported sale, 2,096,504 shares of Guardant Health Common Stock are shown as indirectly owned. These holdings are reported as being held by the Talasaz and Eskandari 2017 Family Trust rather than directly in AmirAli Talasaz’s name.

Is the recent Guardant Health (GH) insider sale classified as an open-market transaction?

Yes. The Form 4 classifies the transaction as an open-market sale of Common Stock, using transaction code “S.” The filing describes it as a sale in the open market or a private transaction, with the shares sold across multiple price points.

Who legally holds the Guardant Health (GH) shares involved in the Form 4 transaction?

The shares are reported as indirectly owned and held by the Talasaz and Eskandari 2017 Family Trust. The Form 4 lists ownership type as indirect, with the nature of ownership explicitly referencing this family trust as the holding entity.